Search Result

Results for "

FAAH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FAAH (99) 5-HT Receptor (2) Apoptosis (1) Autophagy (30) Bacterial (2) Biochemical Assay Reagents (2) Cannabinoid Receptor (6) Ceramidase (4) Cholinesterase (ChE) (1) COX (5) DAGL (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (19) Environmental Pollutants (1) Epoxide Hydrolase (2) Fluorescent Dye (1) Fungal (2) Glutathione Peroxidase (2) Histamine Receptor (1) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (1) MAGL (23) Mitophagy (2) NEDD8-activating Enzyme (1) Nucleoside Antimetabolite/Analog (2) Phospholipase (1) Potassium Channel (1) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (12) SARS-CoV (3) Small Interfering RNA (siRNA) (5) Thyroid Hormone Receptor (1) TRP Channel (6) Tyrosine Hydroxylase (1) Virus Protease (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (4) Endocrinology (1) Infection (8) Inflammation/Immunology (27) Metabolic Disease (26) Neurological Disease (69)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (3) siRNAs (5)

132

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: FAAH

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14595

Biochanin A Maximum Cited Publications 15 Publications Verification 4-Methylgenistein; Olmelin	FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B1227

Carprofen 5+ Cited Publications	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target *FAAH/COX* inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-10864

URB-597 5 Publications Verification KDS-4103	FAAH Autophagy Mitophagy	Neurological Disease
URB-597 (KDS-4103) is an orally bioavailable and selective *FAAH* inhibitor. URB-597 inhibits FAAH activity with an IC₅₀s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .

HY-14380

PF-3845 2 Publications Verification	FAAH Autophagy	Inflammation/Immunology Cancer
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a K_i of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .

HY-14376

Redafamdastat 5+ Cited Publications PF-04457845	FAAH Autophagy	Neurological Disease
Redafamdastat (PF-04457845), a chemical probe, is a highly efficacious and selective *FAAH* inhibitor with IC₅₀ values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.

HY-116477

URB937	FAAH	Neurological Disease Inflammation/Immunology
URB937 is an orally active and peripherally restricted *FAAH* inhibitor (IC₅₀=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .

HY-18540

KT109 1 Publications Verification	MAGL DAGL	Metabolic Disease Inflammation/Immunology
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC₅₀ of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC₅₀=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-10862

FAAH inhibitor 1 Benzothiazole analog 3	FAAH Autophagy	Neurological Disease Cancer
FAAH inhibitor 1 (compound 3) is a selective reversible *FAAH* inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC₅₀ value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research .

HY-N2365

Macamide B 2 Publications Verification N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1	FAAH Autophagy	Others
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-19740

BIA 10-2474 2 Publications Verification	FAAH Autophagy	Neurological Disease
BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC₅₀ values of 50 to 70mg/kg in various rat brain regions.

HY-10865

LY2183240 3 Publications Verification	FAAH Autophagy	Neurological Disease
LY2183240 is a highly potent blocker of anandamide uptake (IC₅₀= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase *(FAAH)* with an IC₅₀ of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC₅₀s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .

HY-77491

FAAH/MAGL-IN-5	FAAH MAGL	Neurological Disease
AM6701 is a potent *FAAH/MAGL* inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

HY-18081

PF 750	FAAH Autophagy	Neurological Disease Metabolic Disease
PF 750 is a selective, covalent and brain-penetrant fatty acid amide hydrolase (FAAH) inhibitor. PF 750 covalently carbamylates FAAH's catalytic serine nucleophile to inactivate the enzyme .

HY-N7062

JNJ-1661010 Takeda-25	FAAH	Neurological Disease
JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .

HY-110138

PDP-EA	FAAH	Others
PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .

HY-N2512

1-Monomyristin 1 Publications Verification	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal	Infection Cancer
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat *FAAH* and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-120961

Oleoyl ethyl amide N-Ethyloleamide	FAAH	Metabolic Disease
Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .

HY-125967

AM 374	FAAH	Neurological Disease
AM 374 is an fatty acid amide hydrolase *(FAAH)* inhibitor. AM 374 inhibits amidase activity with an IC₅₀ value of 13 nM. AM 374 can be used for the research of neurological disease .

HY-19636

JNJ-42165279	FAAH Autophagy	Neurological Disease
JNJ-42165279 is an orally active *FAAH* inhibitor, with IC₅₀ values of 70 nM for hFAAH and 313 nM for rFAAH. JNJ-42165279 can be used in research related to the field of neuropathic pain .

HY-79511

FAAH-IN-2 1 Publications Verification O-Desmorpholinopropyl Gefitinib	FAAH Autophagy	Others
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of *FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895)* .

HY-120957

AMC Arachidonoyl Amide AMC-AA; 7-Amino-4-methyl coumarin-arachidonamide	Endogenous Metabolite	Metabolic Disease
AMC arachidonoyl amide (AMC-AA) is one of several fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate anandamide.2 Exposure of AMC-AA to FAAH activity results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm. This allows the fast and convenient measurement of FAAH activity using a simple cuvette or microplate fluorometer.

HY-177093

Irafamdastat BMS-986368; CC-97489; ABX-1772	MAGL FAAH	Neurological Disease
Irafamdastat (BMS-986368) (Example 74) is a *FAAH* and MAGL inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect .

HY-118158

FAAH/MAGL-IN-4	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-122159

MDPD	FAAH	Metabolic Disease
MDPD is an Arabidopsis FAAH (AtFAAH) activator that can enhance the enzymatic activity of AtFAAH .

HY-18544

AA38-3	MAGL FAAH	Metabolic Disease
AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

HY-103462

TC-F2	FAAH	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-N2428

N-(3-Methoxybenzyl)Palmitamide	FAAH	Neurological Disease
N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of *FAAH* for the treatment of pain, inflammation and CNS degenerative disorders .

HY-118653

SAR629	MAGL	Metabolic Disease
SAR629 is a potent monoglyceride lipase (MGL) covalent inhibitor. SAR629 also inhibits 2-Arachidonoylglycerol (2-AG) degradation .

HY-152254

*CB2R/FAAH* modulator-3**	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and *FAAH* inhibitor. The K_i values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

HY-152251

*CB2R/FAAH* modulator-1**	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-123863

SSR411298	FAAH	Neurological Disease
SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .

HY-14595R

Biochanin A (Standard) Maximum Cited Publications 15 Publications Verification 4-Methylgenistein(Standard); Olmelin (Standard)	Reference Standards FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-163733

AKU-005	FAAH MAGL	Neurological Disease Inflammation/Immunology
AKU-005 is a *FAAH* and MAGL dual inhibitor with IC₅₀ values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia .

HY-B1227R

Carprofen (Standard)	Reference Standards COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-175816

*5-HT6R/FAAH* modulator 1**	5-HT Receptor FAAH Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pK_i of 6.33 (5-HT6) and a pIC₅₀ valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC₅₀ = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .

HY-111389

FAAH-IN-1	FAAH Autophagy	Metabolic Disease
FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

HY-103461

FAAH-IN-6	FAAH	Neurological Disease
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .

HY-144738

*Dual FAAH/sEH-IN-1*	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and *FAAH* (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

HY-116798

URB524	FAAH	Neurological Disease
URB524 is an irreversible *FAAH* inhibitor of O-aryl amino acid esters. URB524 inhibits FAAH by aminoformylation of Ser241. URB524 exhibits analgesic, antidepressant, and anti anxiety activity .

HY-157132

FAAH-IN-8	FAAH	Neurological Disease
FAAH-IN-8 (compound 11) is a competitive inhibitor of FAAH with an IC₅₀ value of 6.7 nM and a K_i value of 5 nM. FAAH-IN-8 has high blood-brain permeability and a significant antioxidant profile with no neurotoxicity .

HY-138693

ST4070	FAAH	Neurological Disease
ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .

HY-139384

FAAH inhibitor 2	FAAH	Neurological Disease
FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC₅₀ of 0.153 μM .

HY-118210

PHOP	FAAH	Metabolic Disease
PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.

HY-126720

N-Lignoceroyl Taurine	Endogenous Metabolite	Metabolic Disease
N-Lignoceroyl Taurine is an arachidonoyl amino acid and taurine conjugate with a fatty acid that can be isolated from bovine brain. N-Lignoceroyl Taurine is one of several novel taurine-conjugated fatty acids discovered during mass spectrometry lipidomic analysis of the brain and spinal cord of wild-type and fatty acid amide hydrolase (FAAH) knockout mice. N-Lignoceroyl Taurine levels were 23-26-fold higher in FAAH ^-/- mice compared to wild-type mice, suggesting that FAAH utilizes N-Lignoceroyl Taurine as a substrate. However, in vitro experiments with purified FAAH showed that N-Lignoceroyl Taurine was hydrolyzed 2,000-fold slower in FAAH compared to oleoylethanolamide. N-Acyl Taurines with polyunsaturated acyl chains can activate members of the transient receptor potential (TRP) calcium channel family, including TRPV1 and TRPV4.

HY-18080

SA 47	FAAH Autophagy	Metabolic Disease
SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate .

HY-B1227S

Carprofen-d3	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N3033

N-Benzyllinolenamide 1 Publications Verification	FAAH Autophagy	Metabolic Disease
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM .

HY-152253

*CB2R/FAAH* modulator-2**	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-2 (compound 26) is a dual targeting modulator that acts as a CB2R agonist and *FAAH* inhibitor. The K_i values for CB2R/FAAH modulator-2 are 10.8 and 152.9 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 6.2 μM. CB2R/FAAH modulator-2 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

HY-121090

FAAH-IN-9	FAAH	Metabolic Disease
FAAH-IN-9 (compoud 59) is an irreversible oleoyl inhibitor of FAAH with Ki of 0.02 nM.

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library

978 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 978 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L013

Neuronal Signaling Compound Library

3,802 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,802 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.	Product Name	Type

HY-120971

N-Decanoyl p-Nitroaniline

DepNA

Fluorescent Dye

N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.

HY-W479534

Decanoyl m-Nitroaniline DemNA	Fluorescent Dye
Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14595

Biochanin A Maximum Cited Publications 15 Publications Verification 4-Methylgenistein; Olmelin	Neurological Disease Classification of Application Fields Trifolium pratense Linn. Plants Flavonoids Leguminosae Sunscreen Phenols Polyphenols Cosmetic Research Disease Research Fields Isoflavones Source Classification Cancer	FAAH Autophagy Endogenous Metabolite
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B1227

Carprofen 5+ Cited Publications	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	COX FAAH Autophagy Endogenous Metabolite
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target *FAAH/COX* inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N2365

Macamide B 2 Publications Verification N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1	Alkaloids other families Classification of Application Fields Other Alkaloids Other Diseases Plants Disease Research Fields Source Classification	FAAH Autophagy
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-N2512

1-Monomyristin 1 Publications Verification	Infection Structural Classification Serenoa repens Classification of Application Fields Palmae Plants Disease Research Fields Steroids	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat *FAAH* and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-N2428

N-(3-Methoxybenzyl)Palmitamide	Natural Products other families Plants Source Classification	FAAH
N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of *FAAH* for the treatment of pain, inflammation and CNS degenerative disorders .

HY-14595R

Biochanin A (Standard) Maximum Cited Publications 15 Publications Verification 4-Methylgenistein(Standard); Olmelin (Standard)	Flavonoids Neurological Disease Classification of Application Fields Leguminosae Sunscreen Phenols Cosmetic Research Trifolium pratense Linn. Plants Disease Research Fields Source Classification Cancer	Reference Standards FAAH Autophagy Endogenous Metabolite
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B1227R

Carprofen (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards COX FAAH Autophagy Endogenous Metabolite
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N3033

N-Benzyllinolenamide 1 Publications Verification	Alkaloids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	FAAH Autophagy
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM .

HY-W751418

N-Nervonoyl taurine (Z)-2-tetracos-15-enamidoethanesulfonic acid	Natural Products Endogenous metabolite Source Classification	FAAH
N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .

HY-N15826

RBM1-151	Lipid	Fluorescent Dye Ceramidase
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (E_x/E_m). RBM1-151 is hydrolyzed by acid ceramidase (AC) (( ^appK_m = 7.0 μM; ^appV_max = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase ( ^appK_m = 0.73 μM; ^appV_max = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) ( ^appK_m = 3.6 μM; ^appV_max = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer) .

HY-N2365R

Macamide B (Standard) N-Benzylpalmitamide (Standard); N-Benzylhexadecanamide (Standard); Macamide 1 (Standard)	Alkaloids Structural Classification other families Other Alkaloids Plants Source Classification	Reference Standards FAAH Autophagy
Macamide B (Standard) is the analytical standard of Macamide B. This product is intended for research and analytical applications. Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-N2512R

1-Monomyristin (Standard)	Structural Classification Serenoa repens Palmae Plants Steroids	Reference Standards FAAH Bacterial Fungal Endogenous Metabolite Autophagy
1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans .

HY-121557

OMDM-1	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 2.4 μM .

HY-135880A

OMDM-4	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-4 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i 17.7 μM .

HY-135882

OMDM-6	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Cannabinoid Receptor Endogenous Metabolite
OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC₅₀=75 nM) and cannabinoid receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC₅₀ of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-135880

OMDM-3	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

HY-103342

OMDM-2	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 3.0 μM .

Cat. No.	Product Name	Chemical Structure

HY-B1227S

Carprofen-d3
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-B1227S1

Carprofen-13C,d3
Carprofen- ¹³C,d₃ is the deuterium and ¹³C labeled Carprofen . Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Host:	Mouse (2) Rabbit (1)
Reactivity:	Human (3) Mouse (1)
Application:	IHC-P (1) ICC/IF (2) WB (1)
Isotype:	IgG (1) IgG1 (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82319

	FAAH1 Antibody (YA2064) FA2H; FAAH; FAAH-1; Oleamide hydrolase 1; Oleamide hydrolase	WB, IHC-P	Human, Mouse
	FAAH1 Antibody (YA2064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FAAH1.

HY-P88944

	FA2H Antibody (YA8628) FAAH; FAH1; FAXDC1; SCS7; SPG35	ICC/IF	Human
	FA2H Antibody (YA8628) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FA2H.

HY-P88944A

	FA2H Antibody (YA8628)(PBS only) FAAH; FAH1; FAXDC1; SCS7; SPG35	ICC/IF	Human
	FA2H Antibody (YA8628) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FA2H.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-184029

PF-7845yne		Alkynes
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the *FAAH*-anandamide pathway .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FAAH

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products